#ACR20
LightNews LightNews
rheumcat.bsky.social
Wondering if I have the stamina to make a donut thread, to celebrate the anniversary of the #ACR20 Donut Challenge
donuts (berliner) from OARSI 2022 (Berlin) green (matcha) & blue (butterly pea flower) mochi donuts
November 14, 2024 at 1:36 AM
medchemexpress.bsky.social
💊#FDA Approval Update | #Sotyktu (#deucravacitinib): a #TYK-targeting therapy for adults with active #PsA
➡️To manage #skin & #joint symptoms
✅Significant #ACR20 responses in Phase 3 POETYK PsA-1 and PsA-2 trials
#PsoriaticArthritis #Autoimmune #AutoimmuneDisease
March 10, 2026 at 9:10 AM
ard.eular.org
🧪 Late-breaking APEX trial results!
In active PsA pts (≥3 TJC/SJC, CRP ≥0.3, erosions on X-ray), GUS Q4W & Q8W 🆚 PBO showed:
🦴 Less radiographic progression at W24 (vdH-S: 0.55/0.54 vs 1.35; P=0.002/<0.001)
💪 Higher ACR20 responses
#EULAR2025
Posted by @jgletarouilly.bsky.social
June 14, 2025 at 10:54 AM
allcatsrescue.bsky.social
Happy Caturday from Genevieve, who is daydreaming about having a forever home of her own
❤️
Go to our website to apply for adoption (we’re in Hampshire, UK):
allcatsrescue20.wixsite.com/acr20/adopti...
#adoptdontshop #rescuecat #caturday #adoptacat
November 16, 2024 at 4:21 PM
rheumnow.bsky.social
Topline results from Phase 3b APEX study, comparing guselkumab to placebo in biologic naive #PsA pts - showed significant improvement by ACR20 and significantly less Xray progression of structural damage (vs PB) at Week 24
www.jnj.com
April 4, 2025 at 4:03 PM
rheumnow.bsky.social
Metanalysis of calcineurin inhib. in RA - 11 RCTs, 1793 RA pts. Cyclosporin (CSA( (RR 1.6 & Tacrolimus (TAC (RR 2.1) signif improved ACR20 responses. CSA was dose dependent, less so w/ TAC. Both require serum Creat. monitoring consistent increase in s-Cr onlinelibrary.wiley.com/doi/pdf/10.1...
onlinelibrary.wiley.com
March 13, 2026 at 2:01 PM
rheumnow.bsky.social
SetPoint Medical has applied to FDA for pre-market approval of Vagal nerve neuroimmune modulation device to Rx mod-severe #RA, not responding to 2 biologics. Based on RESET-RA 242 pt, 12 wk RCT showing ACR20=35% vs 24% PBO resp. SAE only 1.7%.
SetPoint Medical Releases Positive RESET-RA Study Results
New study data shows positive clinical benefits of SetPoint Medical's neuroimmune modulation treatment for rheumatoid arthritis.
buff.ly
January 14, 2025 at 3:00 PM
rheumnow.bsky.social
BMS announced new data from Phase 3 POETYK PsA-2 trial - Sotyktu (deucravacitinib)vs apremilast vs PBO in PsA w/ higher ACR20 vs PBO at Week 16 (54% vs 39%). AEs led to discontinuation in 1.3% (PBO), 2.2% (Deuc) and 10.5% (apremilast).
Bristol Myers Squibb Reports Positive Phase 3 Data for Sotyktu in Psoriatic Arthritis
Bristol Myers Squibb Reports Positive Phase 3 Data for Sotyktu (Deucravacitinib) in Psoriatic Arthritis, Demonstrating Significant Improvement in Symptoms
buff.ly
March 11, 2025 at 2:00 PM
rheumnow.bsky.social
Comparative efficacy of tofacitinib vs. adalimumab in RA - metanalysis of 9 RCTs, 24,643 pts finds Tofa signif superior to ADA for ACR20 (RR 1.28), HAQ-DI, VAS, but no difference in adverse events (RR 0.96) or DAS28-CRP improvement www.frontiersin.org/journals/pha...
Frontiers | Comparative effectiveness and safety of tofacitinib vs. adalimumab in patients with rheumatoid arthritis: A systematic review and meta-analysis
ObjectivesTo provide the latest systematic review and meta-analysis comparing the effectiveness and safety of tofacitinib and adalimumab in rheumatoid arthri...
www.frontiersin.org
June 10, 2025 at 9:01 PM
rheumnow.bsky.social
FDA has approved deucravacitinib (Sotyktu) the Treatment of Adults with Active Psoriatic Arthritis based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. Sotyktu is the only tyrosine kinase 2 (TYK2) inhibitor to be approved for PsA news.bms.com/news/corpora...
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials…
news.bms.com
March 8, 2026 at 12:06 AM
acr-journals.bsky.social
Intravenous secukinumab in adults with psoriatic arthritis, Phase III INVIGORATE-2 Study:
IV secukinumab demonstrated rapid and sustained improvements in clinical measures of PsA, with safety profile consistent with subcutaneous secukinumab

In A&R
acr.tw/3XQVJmI
🩺
Figure 2. Proportion of patients with PsA who achieved ACR50 (A) or ACR20 (B) through Weeks 16 (nonresponder imputation) and 52 (observed data)ACR, American College of Rheumatology; IV, intravenous; PsA, psoriatic arthritis. Unshaded area of the graph represents data reported using non-responder imputation; shaded area represents time points where data are reported as observed.* P<.0005 vs placebo.** P<.0001 vs placebo.
September 24, 2024 at 8:58 PM
rheumnow.bsky.social
Otilimab, GM-CSF mAb, may have potential in #RA. Metanalysis of 4 RCTs, w/ 3933 RA pts had Moderate evidence for ACR20 (vs PBO) at 90 mg (RR 1.50) & 150 mg (RR 1.39). but neither had signif different adverse events vs PBO. OTIL was less effective than tofacitinib. link.springer.com/article/10.1...
The safety and efficacy of otilimab for rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials - The Egyptian Journal of Internal Medicine
Background Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and damage, affecting millions globally. Despite treatment advancements, achieving remission…
link.springer.com
June 10, 2025 at 3:02 PM
rheumnow.bsky.social
SELECT-PsA 2 subanalysis of 195 active PsA not responding to TNFi shows switching to upadacitinib 15 (vs PB) was superior @wk 24 - ACR20 (58% vs 22%), ACR50 (38% vs 9.5%), ACR70 (22% vs 0%), MDA (24% vs 3%) & maintained thru wk 152. Switching MOAs makes sense! buff.ly/EMFj2Yi
August 31, 2026 at 7:22 PM
rheumnow.bsky.social
Spyre Therapeutics topline results of its anti-TL1A Ab (SPY072) in RA sub-study: Ph 2 SKYWAY 12wk RCT showed 2 doses SPY072 were signif better vs PBO for ACR20 (63% & 58% vs 43%), ACR50 (31% &38% vs 19%), DAS28-CRP reductions (-1.5 & -1.9 vs -1.3) crweworld.com/article/news...
August 27, 2026 at 2:00 PM
stocktitan.net
#SYRE Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

https://www.stocktitan.net/news/SYRE/spyre-therapeutics-announces-topline-results-from-the-rheumatoid-ix2dtm3gbnk8.html
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Spyre Therapeutics (NASDAQ: SYRE) reported topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial of TL1A antibody SPY072. The low dose achieved a statistically significant improvement vs placebo on the primary endpoint DAS28-CRP at Week 12 (-1.9 vs -1.3; p&lt;0.05). High-dose SPY072 showed nominally significant benefit on ACR20 (63% vs 43%), while low dose showed nominally significant benefit on ACR50 (38% vs 19%). Both doses reached target drug levels and provided complete suppression of free TL1A through Week 12, indicating full target engagement.SPY072 was well tolerated, with adverse events in 27% of active vs 36% of placebo patients, mostly mild or moderate; one serious TEAE occurred per arm, none drug-related, and one death occurred on placebo. Spyre said the efficacy magnitude did not meet its internal bar to prioritize SPY072 RA monotherapy, but the data support broader TL1A potential and ongoing trials in PsA, axSpA, ulcerative colitis and hidradenitis suppurativa, with multiple topline readouts expected from late 2026 through 2028.
www.stocktitan.net
August 25, 2026 at 8:01 PM
rheumnow.bsky.social
MoonLake announced positive phase 3 data from IZAR-1 RCT using dual A/F IL-17 inhibitor sonelokimab, showing significant responses at week 16: 66% ACR20, 42% ACR50, 41% minimal disease activity (MDA), & 61% PASI90 at week 16. a 2nd IZAR-2 PsA RCT is in progress www.fiercebiotech.com/biotech/moon...
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab. | MoonLake Immunotherapeutics announced…
www.fiercebiotech.com
August 11, 2026 at 9:32 PM
acr-journals.bsky.social
Phase 3 study of deucravacitinib (TYK2 inhibitor) in psoriatic arthritis with prior intolerance or inadequate response to non- biologic therapies or TNFi

Arthritis & Rheumatology
doi.org/10.1002/art....

Figure: ACR20/50/70 changes through week 52 (nonresponder imputation)
ACR20/50/70 changes through week 52 (nonresponder imputation)
July 22, 2026 at 12:18 PM
abangelabs.bsky.social
FDA expands SOTYKTU label to active psoriatic arthritis with dual phase 3 RCT support https://www.mattheneus.com/editorial/fda-sotyktu-psoriatic-arthritis-efficacy-supplement-acr20-lineage-2026-03-06 #HTA #RegulatoryAffairs #EvidenceSynthesis
March 23, 2026 at 3:33 PM
longtail-news.bsky.social
Feed: "Medical News, Health News Latest, Medical News Today - Medical Dialogues |"
By: Dr. Kamal Kant Kohli on Monday, August 18, 2025
Tildrakizumab Shows Significant Efficacy in Psoriatic Arthritis Phase 3 Trials
Phase 3 trials have demonstrated that tildrakizumab 100mg significantly improved ACR20 response rates in patients with active psoriatic arthritis at 24 weeks compared to placebo, marking a...
medicaldialogues.in
August 19, 2025 at 4:31 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01316301.jpg
#epsteinweb #efta01316301
https://epsteinweb.org
EFTA01316243 | EFTA01316301 IIIII :;:cingular Rarer Baling Cycle Dale: Account Rumba: 14 of 34 03/01106 .03(28106 Call Detail (Continued) I ,541 NallX5 NIA RIJN °DUCK cen t omeon(CL ) AU -Mail,* Oa -Boma. BU-Bushnell. CH -alibied. CL-Clrtaos. Ella-Diplaria. FL -511111. ix-blooll Kam. FM-Pon Myen. P-Reit Piave. PIV-Fm WaliC4LOV - Oiiietsville..IX- Jeckmireille. LC-Laft Cur). LB-1.miteirs. MI-Mid.MA-Mariams. MB-Mtiboame. MX-Nero Bncb. 0C-Oiale. OR-0.61.00, PL-Palitile. PC-Pimaa M. PS-Peasmoke PS-Pal SI Jot. SD-SamDeelia. SA -Sanaa* T1I-Tollibassee.TA-Tapx VII-Vem need. NA-Niplts. LK -Likdaml. TV-Tloweimille. SW-Sibling IN. Cat NPARaSZATIOORUMMINW Rale Pitied (Pd.) P-Peak. 0-C4T Ptak. N-NiAhte Call Teo ee -Imonaamial CA Teetniaaled To Mobile Feast I-FIT OamieMae event. mAeopmeied Call Room B-Dired Ma ti Camelot. C-Call Wiiiiig. D -041a Cal d -Directory Assialom Call: 5-CallFormaddis; A -Err (Map meat H-Gromi Mobile le Mcbile CAR. I-laminas Calk l' - Fa Call M- Metille To Mcbde Oaf MAL N- Off.Nemorls CO-Ado DenmadCall Creek IP- Priors/ Mime Samet: Q-V.VPN: k-eoaa midi Mom. S-Slortil Miamian T-Tbret WWI ' UN*: v-Witt ACtivideel Dinka: M- Nisbm and Washed. Number Called Call To WORT CL Rale Rate PeaMin Code Pd we IN rat V Airtime Charge LD DA Total Charge Item Day DM* 341 0)/11 Time 01,43.1. CL 1 341 02/11 03.14.14 TA PORT CL 10/2 X IN 0.00 341 03/11 04315111 TA ICON, CL IIPA2 I 10! 0.00 )45 344 0)/11 0)/1/ 03.3011•1 05:44MI II IVAN NPA2 N N RN RN 0.00 J1 FLU. IL PAW FL 343 02/11 05•59•21 JA NCOMI CL 102 N 145 03/11 07:101m JA PAU. PL WPA2 N Ira RN 349 0)/11 07:461! JIL AMA IL MIA2 N 150 0)/11 09:14Pli JR aCOml CL meA2 N SI 0)/11 09:41mi MI PALM FL NPA2 N )53 0)/11 09:1311 J3 ACISOPL mPA2 35) 0)/11 09:44M1 J1 PALM FL 351 355 0)/11 09:59111 J1 NCONI CL 0)/11 10:04111 in ACOM CL 354 03/11 20: 14PM J1 03/12 02:30A.M 35• 0)/12 359 0.00 0.00 0410 0.00 RN Illy 0.00 0.00 N RN RN 0.00 WPA2 N Mt 0.00 1CPA2 N IAN 0.00 WIA2 N 0.00 ACR20 FL WA, N IM RN J3 PAIN IL 1•462 N RN 0.00 02:33M1 41 ?MOM, CL MA: N NIX 0.00 0)/12 01:30I111 J1 PAIN FL WIA2 N AN 0.00 310 0)/12 04:34114 TA NO3141 CL MPA2 N IAN 0.00 361 03/12 07-44M 01 Oft Or OA/ N MI 0.00 241 0)/12 0) 47111 JA MIMI CL MPA2 N IMF 0.00 143 0)/12 07:12101 01 FMK M FL iso2 N MP 0.00 344 0)/12 00.24111 Tx WCOMI CL MIA, N IMO 0.00 85 0)112 10:03191 IN NNNI CL 11•462 N IRV 0.00 344 )4/ 0)/12 10:07n tm PAW FL WIA2 N Mt 0.00 10, MIMI 10:109! TM cm PAW FL NPA2 N 3411 0)/12 03/12 PAW IL VIA, 349 03/12 10,20/11 TX ,3041 CL 370 0)/12 10:29M TPI )71 0)/1 10:55114 TX 0)/I) 12 )9AS Cm 0)/1 11:47W TA ALWI FL )4Am TN 101040 CI. PAIN IL WPA2 351 371 Sun Ken 373 In 0.00 0.00 0.00 N N 0.00 XPA2 N RS 0.00 PALM FL XpA2 N N 0.00 PALM IL 10A2 N 0.00 MPA2 N I N NIA) N • 0.00 ie/A2 1 * 0.00 ALL.W FL 0.00 )74 375 03/13 0 03/1 07:440! wei 374 02/13 08:23144 TX NCONI CL WPAI P. R 0.00 09:54Am TN MOOMI CL NPA2 11. R 0.00 XPA2 • WIA2 P )71 0)/1) I MIIM 37$ 03/13 09. 54M - PI 379 03/13 09:57M TM PAW IL PAW IL 0.00 • 0.00 0.00 360 03/13 10:05/1( TX NCONI CL INA2 • 361 03/13 10,50X T$ PAW FL 1211.2 • 0.00 301 0)/13 11:02M TX TALLY. FL INA • 0.00 303 03/13 11,114.11 ye man CL MIA2 • WT X240.9'40 r . III R 0.00 A 0.00 / CONFIDENTIAL SDNY_GM_00344398 EFTA_002 17093 EFTA01316301
February 17, 2026 at 12:15 PM
rheumnow.bsky.social
MTX: SC vs Oral? Metanalysis of 9 RCTs, 974 RA pts. Compared w/ oral, SC MTX signif. incr odds of ACR20 (RR=1.15), ACR50 (RR=1.14) & reduced GI adverse events (RR=0.58), diarrhea (RR=0.42): BUT no difference in ACR70, DAS28-ESR, bioavailability AUC, or other AE www.frontiersin.org/journals/imm...
Frontiers | Subcutaneous methotrexate compared with oral methotrexate in rheumatoid arthritis: a systematic review and meta-analysis
Objectives: To integrate evidence from randomized controlled trials (RCTs) comparing subcutaneous (SC) and oral methotrexate (MTX) for rheumatoid arthritis (...
www.frontiersin.org
June 16, 2026 at 9:09 PM
rheumnow.bsky.social
SOLSTICE: phase 3b RCT guselkumab vs PBO in 451 active PsA pts(GUS q4wk vs q8wk vs PBO). @wk 24 GUS signif better than PBO-ACR20 (59%/62% vs 35%), ACR50 (31%/32% vs 12%), ACR70 (17%/17% vs 2%), PASI 90 (49%/45% vs 12%), MDA (19%/24% vs 5%) ction) acrjournals.onlinelibrary.wiley.com/doi/10.1002/...
Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of the Phase 3, Randomized, Placebo‐Controlled SOLSTICE Study
Objective Evaluate the efficacy and safety of guselkumab, an interleukin-23p19-subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy…
acrjournals.onlinelibrary.wiley.com
March 18, 2026 at 4:01 PM
rheumnow.bsky.social
Topline results from Phase 3b APEX study, comparing guselkumab to placebo in biologic naive #PsA pts - showed significant improvement by ACR20 and significantly less Xray progression of structural damage (vs PB) at Week 24 buff.ly/71yWNUK
April 8, 2025 at 7:15 AM
sciencebriefing.bsky.social
A New IL-17A Inhibitor Shows Promise for Psoriatic Arthritis

A New IL-17A Inhibitor Shows Promise for Psoriatic Arthritis A phase 2 clinical trial has demonstrated the efficacy of vunakizumab, a novel humanized monoclonal antibody targeting interleukin-17A (IL-17A), in patients with active…
A New IL-17A Inhibitor Shows Promise for Psoriatic Arthritis
A New IL-17A Inhibitor Shows Promise for Psoriatic Arthritis A phase 2 clinical trial has demonstrated the efficacy of vunakizumab, a novel humanized monoclonal antibody targeting interleukin-17A (IL-17A), in patients with active psoriatic arthritis. The study randomized patients to receive subcutaneous injections of either 120 mg or 240 mg of vunakizumab, or a placebo, over 12 weeks. The primary endpoint was the American College of Rheumatology 20% improvement (ACR20) response rate.
blog.sciencebriefing.com
February 13, 2026 at 3:31 AM